Proinflammatory Th17 in patients following allo-SCT. (A) Representative FACS analysis and (B) proportion of peripheral blood CD4⁺IL-17A⁺ T cells expressing IFNγ in healthy donors and d14, d120, and d240 after clinical allo-SCT and CsA treatment (∼d0-d100) (mean ± SEM, d14, n = 11 patients, d240, n = 12 patients). (C) Total IL-17A⁺IFNγ⁺ concentrations in human peripheral blood d14 and d240 after clinical allo-SCT and CsA treatment (mean ± SEM, d14, n = 10 patients, d240, n = 10 patients, ***P < .001). (D) Proportion of human peripheral blood IL-17A⁺IFNγ⁺ and IL-17A⁺IFNγ^– CD4⁺ T cells coexpressing TNF on d14, d120, and d240 posttransplant (paired analyses, d14, n = 6 patients, d120, n = 3 patients, and d240, n = 12 patients, *P < .05, **P < . 01, ***P < .001). (E) Pearson correlation analysis of systemic IL-17A and IFNγ concentrations in healthy donor plasma. (F) Cross-correlation analysis of systemic IL-17A, IFNγ, and TNF concentrations in patient plasma over time derived from allo-SCT recipients on days −7, 0, 7, 14, 30, 60, 90, 120, 180, 240, and 360 (n = 53 patients, ***P < .001). n.s., not significant; TNF+ve, tumor necrosis factor positive.